Literature DB >> 18180353

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.

Helio S Sader1, Thomas R Fritsche, Ronald N Jones.   

Abstract

Two investigational anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) beta-lactams, ceftaroline (a cephalosporin) and ME1036 (a carbapenem), were subjected to susceptibility testing by reference broth microdilution methods using 152 strains of community-acquired MRSA from the United States (47 medical centers). Ceftaroline and ME1036 were 64- and >128-fold more potent than ceftriaxone, respectively. All isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type IV, while 67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180353      PMCID: PMC2258508          DOI: 10.1128/AAC.01351-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Staphylococcus aureus infections.

Authors:  F D Lowy
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

2.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 3.  Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.

Authors:  Karen Bush; Markus Heep; Mark J Macielag; Gary J Noel
Journal:  Expert Opin Investig Drugs       Date:  2007-04       Impact factor: 6.206

4.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

5.  Comparison of activities of beta-lactam antibiotics against Streptococcus pneumoniae with recombinant penicillin-binding protein genes from a penicillin-resistant strain.

Authors:  Kumiko Maeda; Takashi Ida; Yumiko Sanbongi; Takahisa Suzuki; Takayoshi Fukushima; Mizuyo Kurazono; Minoru Yonezawa; Kimiko Ubukata; Matsuhisa Inoue
Journal:  J Infect Chemother       Date:  2005-04       Impact factor: 2.211

6.  In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci.

Authors:  Mizuyo Kurazono; Takashi Ida; Keiko Yamada; Yoko Hirai; Takahisa Maruyama; Eiki Shitara; Minoru Yonezawa
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.

Authors:  Cédric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Françoise Miègeville; Antoine Hamel; Denis Bugnon; James Yigong Ge; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

Review 8.  The molecular evolution of methicillin-resistant Staphylococcus aureus.

Authors:  R H Deurenberg; C Vink; S Kalenic; A W Friedrich; C A Bruggeman; E E Stobberingh
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

9.  Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections.

Authors:  Mark D King; Bianca J Humphrey; Yun F Wang; Ekaterina V Kourbatova; Susan M Ray; Henry M Blumberg
Journal:  Ann Intern Med       Date:  2006-03-07       Impact factor: 25.391

10.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Authors:  Yuji Iizawa; Junko Nagai; Tomoyasu Ishikawa; Shohei Hashiguchi; Masafumi Nakao; Akio Miyake; Kenji Okonogi
Journal:  J Infect Chemother       Date:  2004-06       Impact factor: 2.211

View more
  23 in total

1.  PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  S Wesley Long; Randall J Olsen; Shrenik C Mehta; Timothy Palzkill; Patricia L Cernoch; Katherine K Perez; William L Musick; Adriana E Rosato; James M Musser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 2.  Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

Authors:  Leticia I Llarrull; Jed F Fisher; Shahriar Mobashery
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

4.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

Authors:  Delphine Croisier-Bertin; Lionel Piroth; Pierre-Emmanuel Charles; Aurélie Larribeau; Donald Biek; Yigong Ge; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 7.  Resisting resistance: gearing up for war.

Authors:  Aurijit Sarkar; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2019-08-07       Impact factor: 3.597

8.  In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.

Authors:  Delphine Croisier-Bertin; Davy Hayez; Sonia Da Silva; Delphine Labrousse; Donald Biek; Cedric Badiou; Oana Dumitrescu; Pascal Guerard; Pierre-Emmanuel Charles; Lionel Piroth; Gerard Lina; Francois Vandenesch; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

Review 9.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval.

Authors:  Todd A Riccobene; Ludmyla Rekeda; Douglas Rank; Lily Llorens
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.